undamentalytics Newsletter
Sign in

Tela Bio, Inc. cash flow statement

In fiscal 2025, Tela Bio, Inc.'s operations generated −$28.2m of cash; it spent $448,000 on capital projects, leaving free cash flow of −$28.7m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−16−20−26−24−30−41−41−42−28−31
Depreciation and amortisation1000000111
Stock-based pay0002445443
Capital spending0000111100
Free cash flow−16−20−26−25−31−42−41−43−29−32
Free cash flow after stock pay−17−20−26−27−35−46−47−47−32−35
Shares issued———45—3446———

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: PDEX vs TELASGHT vs TELARCEL vs TELAELMD vs TELA

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Tela Bio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Tela Bio, Inc.